Skip to main content

Table 2 Use of second generation antipsychotics, mood stabilizers and SSRI/SNRIs

From: A Canadian naturalistic study of a community-based cohort treated for bipolar disorder

Medication* Baseline One Month
  Olanzapine
(n= 287)
Other
(n= 209)
Olanzapine
(n= 270)
Other
(n= 200)
SGA + Mood
Stabilizer
97 (34%) 55 (26%) 90 (33%) 60 (30%)
SGA Alone 87 (30%) 42 (20%) 75 (28%) 37 (19%)
SGA + SSRI/SNRI 51 (18%) 23 (11%) 43 (16%) 30 (15%)
SGA + SSRI/SNRI +
Mood Stabilizer
34 (12%) 24 (11%) 39 (14%) 27 (14%)
Mood Stabilizer Alone 8 (3%) 38 (18%) 7 (3%) 28 (14%)
Mood Stabilizer + SSRI/SNRI 5 (2%) 13 (6%) 6 (2%) 8 (4%)
SSRI/SNRI Alone 3 (1%) 8 (4%) 3 (1%) 3 (2%)
  1. SGA: second generation antipsychotic
  2. SSRI/SNRIs: selective serotonin reuptake inhibitors/selective serotonin and norepinephrine reuptake inhibitors: includes citalopram, fluoxetine, paroxetine and venlafaxine
  3. Mood Stabilizer: includes lithium and valproate
  4. *In addition patients may have used benzodiazepines and/or tricyclics